We found out last week that Pfizer had tapped Ian Read’s carefully groomed successor Albert Bourla for the top C-suite post at the pharma giant. And right on the heels of that announcement, Pfizer revealed that they have also decided to shake up the top team that will help determine just how successful Bourla turns out in his new job.
Pfizer is starting by expanding the top group of execs, hiring Lidia Fonseca from Quest Diagnostics to lead up the company’s digital efforts across research, discovery and business processes — following a focus that Novartis and others have put a premium on over the past year. Fonseca’s new title is chief digital officer, or CDO.
Executive vice president and president, PGS, Kirsten Lund-Jurgensen, will retire at the end of the year after 19 years at Pfizer, along with Laurie Olson, EVP of Strategy & Commercial Operations.
Here’s the rest of the lineup, which is retaining some familiar faces.
R&D chief Mikael Dolsten will also assume oversight of the chief medical officer’s role.
The CFO and the head of global supply and business operations Frank D’Amelio will also assume the leadership for their manufacturing operations.
As announced earlier, Michael Goettler will lead the established medicines business “that will operate as an autonomous, stand-alone unit within Pfizer.”
Angela Hwang, group president of Pfizer Innovative Medicines, will become the group president of Pfizer’s “science-based innovative business responsible for the entire portfolio of innovative medicines.”
Chief Business officer John Young “will assume a new role, responsible for strategy, business development, portfolio management and valuation activities; business analytics; global commercial operations; and Patient and Health Impact, among others.” Pfizer’s Consumer Healthcare business will also report to him.
Chief compliance officer Rady Johnson, general counsel Doug Lankler, HR chief Dawn Rogers and Sally Susman, chief corporate affairs officer, are all keeping the same roles they had earlier.
Image: Albert Bourla. AP IMAGES
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 34,900+ biopharma pros who read Endpoints News by email every day.Free Subscription